Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

Back

ESC Professional Premium Access

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

Session: Improving outcomes in heart failure: bench to bedside

Topic: Aldosterone Antagonists

Speaker: Doctor P. Kolkhof (Wuppertal, DE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Peter Kolkhof

BAYER AG, R&D Pharmaceuticals, Wuppertal (Germany)

0 follower

8 more presentations in this session

Are heart failure patients with mildly reduced ejection fraction treated according to current international guidelines?

Speaker: Doctor T. Schupp (Mannheim, DE)

The power of optimal medical therapy in heart failure with secondary mitral regurgitation

Speaker: Unknown A. Borrellas Martin (Barcelona, ES)

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

Speaker: Doctor F. Hofer (Vienna, AT)

Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model

Speaker: Professor M. Franz (Rotenburg an der Fulda, DE)

Effects of colchicine treatment after myocardial infarction on top of standard therapy: evidence from a preclinical study

Speaker: Doctor A. Aimo (Pisa, IT)

Access the full session

Improving outcomes in heart failure: bench to bedside

Speakers: Doctor P. Kolkhof, Doctor T. Schupp, Unknown A. Borrellas Martin, Doctor F. Hofer, Professor M. Franz...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

About the speaker

Doctor Peter Kolkhof

8 more presentations in this session

Are heart failure patients with mildly reduced ejection fraction treated according to current international guidelines?

The power of optimal medical therapy in heart failure with secondary mitral regurgitation

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model

Effects of colchicine treatment after myocardial infarction on top of standard therapy: evidence from a preclinical study

Access the full session

Improving outcomes in heart failure: bench to bedside

About the event

ESC Congress 2023

ESC 365 is supported by